Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 17924835)

1.
2.

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T.

Drug Metab Pharmacokinet. 2005 Jun;20(3):153-67. Review.

3.

Pharmacogenomics of proton pump inhibitors.

Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T.

Pharmacogenomics. 2004 Mar;5(2):181-202. Review.

PMID:
15016609
4.

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.

Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T.

J Gastroenterol Hepatol. 2002 Jul;17(7):748-53.

PMID:
12121503
5.

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E.

Clin Pharmacol Ther. 2001 Mar;69(3):158-68.

PMID:
11240980
6.

Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.

Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):375-9. Epub 2005 Jun 23.

PMID:
15976989
7.
8.

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.

Furuta T, Sugimoto M, Shirai N.

Mol Diagn Ther. 2012 Aug 1;16(4):223-34. doi: 10.2165/11634960-000000000-00000. Review.

PMID:
22873740
10.

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.

Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH.

Am J Gastroenterol. 2006 Jul;101(7):1467-75.

PMID:
16863547
11.

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.

Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, Sato Y, Kajimura M, Futami H, Takayanagi S, Yamada M, Ohashi K, Ishizaki T, Hanai H.

Clin Pharmacol Ther. 2002 Oct;72(4):453-60.

PMID:
12386647
12.

CYP2C19 genotype and the PPIs--focus on rabeprazole.

Lim PW, Goh KL, Wong BC.

J Gastroenterol Hepatol. 2005 Dec;20 Suppl:S22-8. Review.

PMID:
16359346
13.

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.

Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, Iwaizumi M, Yamade M, Terakawa I, Ohashi K, Ishizaki T, Hishida A.

Clin Pharmacol Ther. 2007 Apr;81(4):521-8. Epub 2007 Jan 10.

PMID:
17215846
14.

Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.

Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G.

Helicobacter. 2008 Dec;13(6):532-41. doi: 10.1111/j.1523-5378.2008.00643.x.

PMID:
19166419
15.
16.
17.

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.

Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K.

Pharm Res. 2001 Jun;18(6):721-7.

PMID:
11474773
18.

CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.

Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Ikuma M, Shirai N, Watanabe H, Umemura K, Kimura M, Hishida A.

Eur J Clin Pharmacol. 2009 Jul;65(7):693-8. doi: 10.1007/s00228-009-0628-5. Epub 2009 Mar 4.

PMID:
19259653
19.

Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.

Chaudhry AS, Kochhar R, Kohli KK.

Indian J Med Res. 2008 Jun;127(6):521-30. Review.

PMID:
18765869
20.

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.

Lee SB, Park SJ, Ryu JK, Lee JK, Kim HJ, Bae JS, Jung HS, Park SM.

Korean J Gastroenterol. 2003 Dec;42(6):468-75.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk